



Use of Vaccinia Virus Vaccine in Persons at Risk for Occupational Exposure to Orthopoxviruses: WG Update

Beth Bell, MD MPH

ACIP WG Chair

University of Washington

February 25, 2021

Reason for Work Group

Update ACIP recommendations to include use of JYNNEOS[®]
to prevent orthopoxviruses in persons at risk for occupational exposure

Work Group Members

ACIP Members

Beth Bell (chair)

Pablo Sánchez

Ex Officio Members

DoD- Jay Montgomery

DoD-Bryan Schumacher

FDA- Sixun Yang, Clement

Meseda & Alonzo García

NIH- Mark Challberg

Liaison Representatives

ACOG- Howard Minkoff

NACCHO- Jee Kim

NACI- April Killikelly

SHEA- David Weber

Invited Consultants

HHS/BARDA- Mike Merchlinksy, Amanda Zarrabian, and Ramya Natarajan

NIH- Heike Bailin

Subject Matter Expert: Stuart Isaacs

APHL- Jafar Razeq

CDC Contributors

Subject Matter Experts-

Inger Damon and Mary Reynolds

Immunization Safety Office-

Mike McNeil

Regulatory Affairs: Yon Yu &

Lisa Hesse

NIOSH: *Marie de Perio*

Drug Services: *Julian Jolly*

Division of Healthcare Quality

Promotion- *David Kuhar*

Laboratory Response Network-

Julie Villanueva

Orthopoxvirus Work Group leads –

Agam Rao & Brett Petersen

ACIP Orthopoxvirus sessions until now

- **October 2019:** Introduced formation of Work Group
- **October 2020**
 - Presented background information about orthopoxvirus vaccinations and ACAM2000
 - Introduced considerations related to use of JYNNEOS® vaccine

Progress since last ACIP meeting

- **Work Group**

- Identified need to address booster vaccination with JYNNEOS[®]
- Discussed how best to consolidate previous ACIP orthopoxvirus recommendations into this update
- Began discussing Evidence to Recommend Framework


- **ACIP leads**

- Continued work on systematic review

WG's goals for today

- Present background information and Work Group considerations in structuring recommendations for use of JYNNEOS
 - Populations at risk for occupational exposure to orthopoxviruses in the pre-event setting
 - Recommendations for booster doses in the context of very limited data
- Describe planned consolidation of various previous ACIP recommendations into a single updated document
- Obtain feedback and discussion about proposed approach

Anticipated timeline



Today's Agenda

- Work Group considerations (Brett Petersen, CDC)
- Updated policy questions for Evidence to Recommendations framework and plan for next steps (Agam Rao, CDC)

Thank you!

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

